Displaying drugs 14676 - 14700 of 15514 in total
Mocemestrocel
Investigational
Ovemotide
Ovemotide is under investigation in clinical trial NCT00357461 (Ipilimumab With or Without Vaccine Therapy in Treating Patients With Previously Treated Stage IV Melanoma).
Investigational
ATG002
ATG002 is a completely new approach to treating chronic wounds such as diabetic foot ulcers, which is based upon stimulation of angiogenesis in the wound bed to help drive the wound-healing process. Unlike protein-derived growth factors, ATG002 is a small molecule that, applied topically, effectively penetrates through the wound and...
Investigational
Matched Description: … factors, ATG002 is a small molecule that, applied topically, effectively penetrates through the wound and …
CRx-119
CRx-119 is a novel synergistic combination drug candidate discovered using the CombinatoRx combination High Throughput Screening (cHTS(TM)) technology with potential therapeutic use in a broad range of immuno-inflammatory conditions. CRx-119 is a combination of a low dose of the steroid prednisolone, 3mg, and amoxapine.
Investigational
Matched Description: … CRx-119 is a combination of a low dose of the steroid prednisolone, 3mg, and amoxapine. …
SR 140333
SR 140333 is tachykinin antagonist which has potential to treat diarrhoea due to food allergy or inflammatory bowel disease.
Investigational
DP-b99
DP-b99 is a newly developed lipophilic, cell permeable derivative of BAPTA (1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid), that is under development as a neuroprotectant for the potential treatment of stroke, head trauma and neurological damage associated with coronary artery bypass graft.
Investigational
Matched Description: … , that is under development as a neuroprotectant for the potential treatment of stroke, head trauma and …
CAM-2029
CAM2029 is a new ready-to-use, long-acting octreotide formulation being developed for the long-term treatment of acromegaly, carcinoid syndrome and vasoactive intestinal peptide (VIP)-producing tumours. CAM2029 was found to provide long-acting release of octreotide resulting in a statistically significant suppression of a clinical biomarker insulin-like growth factor 1 (IGF-1) over the...
Investigational
Matched Description: … octreotide formulation being developed for the long-term treatment of acromegaly, carcinoid syndrome and …
Aminoimidazole carboxamide
Investigational
Zosuquidar
Zosuquidar is a compound of antineoplastic drug candidates currently under development. It is now in "Phase 3" of clinical tests in the United States. Its action mechanism consists of the inhibition of P-glycoproteins; other drugs with this mechanism include tariquidar and laniquidar.
Investigational
Matched Description: … mechanism consists of the inhibition of P-glycoproteins; other drugs with this mechanism include tariquidar and …
Elsiglutide
Investigational
Annamycin
Investigational
Perflubron
Perflubron (Oxygent) is being developed as an intravascular oxygen carrier designed to augment oxygen delivery in surgical patients.
Investigational
5,7-Dichlorokynurenic acid
Experimental
Indirubin-3'-monoxime
Experimental
Pyridoxamine-5'-Phosphate
Experimental
FR236913
Experimental
Indole-3-Propanol Phosphate
Experimental
RU79073
Experimental
2-Amino-3-(1h-Indol-3-Yl)-Propan-1-Ol
Experimental
Fe-Mesopone
Experimental
VX-702
VX-702 is a small molecule investigational oral anti-cytokine therapy for treatment of inflammatory diseases, specifically rheumatoid arthritis (RA). It acts as a p38 MAP kinase inhibitor. In the future, VX-702 may be investigated for combination with methotrexate, a commonly used therapy for RA.
Investigational
4-O-Demethylpenclomedine
Investigational
Displaying drugs 14676 - 14700 of 15514 in total